ATLANTA, Oct. 02, 2026 (GLOBE NEWSWIRE) — Gray Media, Inc. (NYSE: GTN) today announced that it will release its earnings results for the quarter ending September 30, 2026, on Friday, November 6, 2026.

Earnings Conference Call Information

            Gray Media, Inc. will host a conference call to discuss its operating results for the quarter ending September 30, 2026, on Friday, November 6, 2026. The call will begin at 11:00 a.m. Eastern Time. The live dial-in number is 1-800-715-9871 (or 1-646-307-1963.) All participants who dial in will be asked for their name and conference ID (3663076) or the name of the call (Gray Media Q3 Call) and will be placed on music hold prior to the start of the conference. Participants should dial in 10-15 minutes before the conference is scheduled to begin. The call will be webcast live and available for replay at www.graymedia.com. The taped replay of the conference call will be available at 1-800-770-2030 using conference ID 3663076# until December 4, 2026.

About Gray Media

            Gray Media, Inc. (NYSE: GTN) is a multimedia company headquartered in Atlanta, Georgia. We are the nation’s largest owner of top-rated local television stations and digital assets. We serve 117 full-power television markets that collectively reach approximately 37% of US television households. The portfolio includes 78 markets with the top-rated television station and 101 markets with the first and/or second highest rated television station in average all-day ratings across the 116 of such markets that were measured by Nielsen in 2025. We also own the largest Telemundo Affiliate group with 46 markets and Gray Digital Media, a full-service digital agency offering national and local clients digital marketing strategies with the most advanced digital products and services. Our additional media properties include video production companies Raycom Sports, Tupelo Media Group, PowerNation Studios, and studio production facilities Assembly Atlanta and Third Rail Studios.

Gray Contact

Jeff Gignac, Executive Vice President, Chief Financial Officer, 404-504-9828
Alan Gould, Vice President, Investor Relations, 404-266-8333

#         #         #           

Company Announcement

  • Major shareholder announcement for Genmab A/S

COPENHAGEN, Denmark; October 2, 2026 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital Markets Act that Darwin Global Management Limited (“Darwin”) has informed us that, as of September 28, 2026, Darwin through shares and ADRs held by certain investment funds and portfolios for which Darwin acts as investment manager, controls the voting rights attached to 3,188,361 shares in Genmab A/S, corresponding to 5.11% of the voting rights in Genmab A/S.  

About Genmab 
Genmab is an international biotechnology company dedicated to improving the lives of people with cancer and other serious diseases through innovative antibody medicines. For over 25 years, its passionate, innovative and collaborative team has advanced a broad range of antibody-based therapeutic formats, including bispecific antibodies, antibody–drug conjugates (ADCs), immune-modulating antibodies and other next-generation modalities. Genmab’s science powers eight approved antibody medicines, and the company is advancing a strong late-stage clinical pipeline, including wholly owned programs, with the goal of delivering transformative medicines to patients.

Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit Genmab.com or follow us on LinkedIn, X, Facebook and Instagram.

Contact:        
Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs
T: +1 609 524 0065; E: mmp@genmab.com

Andrew Carlsen, Vice President, Head of Investor Relations
T: +45 3377 9558; E: acn@genmab.com

This Company Announcement contains forward looking statements. The words “believe,” “expect,” “anticipate,” “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with preclinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; HexaBody®; DuoHexaBody®, HexElect® and KYSO®.

Company Announcement no. 39
CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122

Genmab A/S
Carl Jacobsens Vej 30
2500 Valby
Denmark

Attachment

Also announces Agreement with Oak Hill Financial and DTC Eligibility

OTTAWA, Ontario, Oct. 02, 2026 (GLOBE NEWSWIRE) — Viridian Metals Inc. (CSE: VRDN) (OTCQB: VIRMF) (“Viridian” or the “Company”) reports additional assay results from its 2026 drill program at the Kraken Main Zone in Labrador and provides an update on major step-out drilling along the southern part of the Main Zone.

Drilling tested approximately 3 kilometres south along Kraken Main, beginning approximately 500 metres south of Viridian’s 2025 drilling infilling to a drill hole completed in 2023. All eight successfully drilled holes along this trend intersected visually identified sulphides, including the same patchy net-textured and semi-massive sulphide styles encountered in the established Main Zone. Laboratory assays are required to determine metal grades.

Highlights

  • 3 km of step-out drilling: All eight successfully drilled holes intersected visually identified patchy net textured sulphides along the southern 3 km of Kraken Main.
  • Broad sulphide-bearing intervals: VKS26-063 intersected 47.3 metres of patchy net-textured sulphides, VKS26-065 intersected 41.8 metres, VKS26-062 intersected 33.2 metres and VKS26-059 intersected 28.0 metres.
  • Semi-massive sulphides in multiple step-outs: VKS26-062 and VKS26-060 intersected 7.7 metres and 6.7m of semi-massive sulphides respectively.
  • Sulphides begin at bedrock and remain open: Seven holes encountered patchy net-textured sulphides from the top of bedrock. Five ended in patchy net-textured sulphides.
  • Additional assays received: from the extension of VKS25-025 and part of VKS25-055.

“These results demonstrate the scale over which we continue to see the same sulphide system at Kraken Main,” said Tyrell Sutherland, President and Chief Executive Officer of Viridian Metals. “Across three kilometres of the southern Main Zone, drilling has now intersected visually identified sulphides at an average spacing of approximately 400 metres, including higher-intensity semi-massive sulphides comparable to our best results to date.”

“Previously, this three-kilometre section of Kraken Main was represented by just two partially analyzed holes spaced more than a kilometre apart and our 2023 drill hole at the southern end. We are now filling in that gap, consistently encountering sulphides from the top of bedrock, with several holes ending in visual mineralization. These results are consistent with the scale of the Main Zone suggested by our interpretation.”

Plan map of the Kraken Main Zone showing 2026 step-out drilling across 3 kilometres of the Main Zone, historical drilling and representative photographs of sulphide textures observed in drill core. Drill core is BTW size with a diameter of 4.2 cm (1.65”) Visual observations have not been confirmed by laboratory analysis. Reported intervals represent downhole lengths; true thicknesses are not yet known.

Figure 1: Plan map of the Kraken Main Zone showing 2026 step-out drilling across 3 kilometres of the Main Zone, historical drilling and representative photographs of sulphide textures observed in drill core. Drill core is BTW size with a diameter of 4.2 cm (1.65”) Visual observations have not been confirmed by laboratory analysis. Reported intervals represent downhole lengths; true thicknesses are not yet known.

Drilling Update

Viridian has two drill rigs on site currently drilling holes VKS26-068 and 069 the 19th and 20th holes so far this season. To date Viridian has drilled ~900m and has seen an uptick in drilled meters by 20% in the month of September as drill crews have settled into an optimal sequencing. Currently both rigs are on the Venus target, following up on a hole drilled in 2023 of 7.55 metres @ 0.4% Ni, 0.2% Cu and 0.05% Co from surface, with associated precious metal values of up to 0.76g/t platinum, 0.33g/t palladium and 0.45g/t gold (see technical report dated September 23, 2024 available on SEDAR+). Viridian will complete the two exploration holes October 5th then both will return to the northern Main Zone to progress with extending holes from Viridian’s 2025 program that ended in the upper disseminated mineralization zones or failed to reach bedrock.

Viridian expects to have initial samples from holes through VKS26-063 processed and delivered to Activation Laboratories Ltd. (“Activation Labs”) in Ancaster, Ontario the week of October 6th, with assay results expected before the end of October. These results will provide the first assays from the major step-out drilling across the southern portion of Kraken Main.

VKS25-025 previously returned 5.25 metres @ 0.24% CuEq¹ from 21 metres and ended in disseminated mineralization at 26.25 metres (see Viridian news release dated February 26, 2026 which is available on the Company SEDAR+ profile at www.sedarplus.ca and the Company’s website at www.viridianmetals.com). Viridian extended this hole this year as it appeared to intersect just the upper portions of the mineralized horizon. The hole was extended to 44.05m continuing with disseminated mineralization to final depth before repairs forced the rig to be demobilized. Final assays from the extended hole returned 23.05 metres @ 0.24% CuEq¹ from 21 metres. The bottom of the hole remains in disseminated mineralization an unknown distance above the main target horizon. If drill sequencing allows, the hole may be further extended in 2026 to attempt to reach the main mineralized horizon, however as one of the Company’s deeper intervals it will be prioritized relative to near-surface mineralization.

Only the first portion of VKS26-055 is reported in this release. The hole was a significant step back from previous drilling and did not reach its intended target depth. Minor isolated zones of sulphide mineralization were encountered in the upper portion of the hole.

Table 1 – Kraken Main Zone drill collars, this release. Collar coordinates are reported in NAD83 / UTM Zone 20N. Azimuths are referenced to true north.

Hole Easting (m) Northing (m) Azimuth (°) Dip (°) Total Depth (m)
VKS25-024e 446089 6020685 112 68 51.15
VKS26-052 446027 6020269 090 73 30.65
VKS26-053 446019 6020362 100 77 11.10
VKS26-054 446139 6020412 102 78 30.90
VKS26-055 446017 6020363 090 80 48.15
VKS25-025e 446039 6020656 105 70 44.05
           

Table 2 – Kraken Main 2026 Drill Results new results are in bold.

Drillhole ID From To Length* Cu Ni Co CuEq¹
  (m) (m) (m) (%) (%) (%) (%)
VKS25-024 1.0 51.15 50.15 0.19 0.26 0.04 0.68
including 12.2 31.0 18.8 0.33 0.43 0.06 1.12
including 19.4 31.0 11.6 0.3 0.5 0.07 1.28
VKS26-052 0.7 3.0 2.3 0.07 0.13 0.03 0.46
and 7.5 15.0 7.5 0.06 0.06 0.01 0.18
and 23.0 24.7 1.7 0.09 0.07 0.02 0.25
and 26.3 29.15 2.85 0.12 0.16 0.01 0.40
VKS26-053 1.5 5.0 3.5 0.05 0.08 0.02 0.21
VKS26-054 0.7 4.0 3.3 0.36 0.67 0.11 1.68
and 11.7 13.0 1.3 0.65 0.81 0.11 2.18
and 17.45 18.75 1.3 0.44 0.83 0.11 2.01
and 20.7 26.9 6.2 0.38 0.57 0.08 1.50
VKS25-025 21.0 44.05 23.05 0.07 0.09 0.01 0.24
VKS25-055 partial 1.0 4.0 3.0 0.07 0.07 0.01 0.2
               

*True thickness of the reported mineralized intervals is not yet known. Reported interval lengths represent downhole core lengths and should not be interpreted as true thickness.

Intercepts are calculated using a 0.1% CuEq¹ cut-off grade corresponding to approximately $10USD NSR with no more than 1.5 m of internal dilution. Viridian has completed specific gravity measurements and full multi-element geochemical analysis on all samples to support ongoing characterization of the Kraken system.

QA/QC

On receipt from the drill site BTW-sized drill core was systematically logged for geological attributes, photographed and sampled at Viridian’s Core Shack at Kraken Camp. Sample lengths as small as 0.30 m were used to isolate features of interest, but most samples within moderate to strong mineralization were 0.5-1.0 m in length. Core was cut in half lengthwise along a pre-determined line, with one half (same half, consistently, dictated by cut line where present) collected for analysis and one half stored as a record. Standard reference materials and blanks were inserted by Viridian personnel at regular intervals into the sample stream. Bagged samples were sealed with security tags to ensure integrity during transport. They were delivered by expeditor to Activation Labs’ facility in Ancaster, ON.

Activation Labs is independent of Viridian and accredited to ISO/IEC 17025. Samples were dried, crushed (< 7 kg) up to 80% passing 2 mm using riffle split (250 g) and pulverized to 95% passing 105 µm (code RX1). A four-acid near-total digest with an inductively coupled plasma optical emission spectroscopy (ICP-OES) finish was used for 35-element analysis on 25 g sample pulps (code 1F2). Samples that were over the analyses limit for Co, Cu and Ni were reanalyzed using sodium peroxide fusion ICP (code 8-peroxide).

Qualified Person

Tyrell Sutherland, P.Geo, President and CEO of Viridian Metals, who is a Qualified Person as defined in National Instrument 43-101 – Standards of Disclosure for Mineral Projects, has reviewed and approved the technical disclosure contained in this news release.

¹Copper Equivalent Calculation

CuEq¹ calculated based on the following metal prices (USD): $4.00/lb Cu, $7.50/lb Ni and $15.00/lb Co, and a recovery grade of 80% for Ni and Co, consistent with comparable peers. The Company believes that all metals included in the CuEq¹ calculation have a reasonable potential to be recovered. CuEq¹ values are provided for illustrative purposes only; actual recoveries and metal prices may differ materially from those assumed.

Agreement with Oak Hill Financial

The Company is further pleased to announce that it has engaged Oak Hill Financial Inc. (“Oak Hill”), a Toronto-based investor engagement and capital markets advisory firm, to provide business and capital markets advisory, marketing and investor relations services.

Under the terms of the engagement, Oak Hill will act as an advisor to the Company, with a mandate to enhance Viridian’s visibility and engagement within the investment community. Services will include targeted outreach to investment advisors and institutional investors, assisting with the development and dissemination of the Company’s investor presentation and other marketing materials, and providing monthly progress reports to the Company. Where required, Oak Hill may engage its affiliate, Oak Hill Asset Management, a registered exempt market dealer, at no additional cost to the Company. The Company confirms that Oak Hill Financial Inc. is arm’s length to the Company.

The agreement became effective September 16, 2026, has an initial term of two months, and may be extended by the Company on a month-to-month basis. Oak Hill will receive a monthly advisory fee of C$12,000, plus applicable taxes, and will be reimbursed for pre-approved out-of-pocket expenses. Oak Hill’s business address is 2 Bloor Street West, Suite 2900, Toronto, Ontario M4W 3E2, and its contact is Anil Singh, Managing Partner 1(647)-215-8372.

The Company confirms that no securities of the Company have been granted to Oak Hill or its principals as compensation for the services to be provided under the agreement. Oak Hill does not have any direct or indirect interest in the securities of the Company, nor does it have any right or intent to acquire such an interest, except as may be purchased in the open market. The services to be provided by Oak Hill will include investor relations and marketing activities within the meaning of applicable securities laws and the policies of the Canadian Securities Exchange.

DTC Eligibility

Finally, Viridian is pleased to announce that its common shares are now eligible for electronic clearing and settlement in the United States through the Depository Trust Company (“DTC”).

DTC eligibility is expected to simplify the process of trading and enhance liquidity of Viridian’s shares in the United States. The Company’s shares recently began trading on the OTCQB® Venture Market (“OTCQB”) under the ticker symbol VIRMF.

DTC is a subsidiary of the Depository Trust & Clearing Corporation, a U.S. company that manages the electronic clearing and settlement of publicly traded securities. Securities that are eligible to be electronically cleared and settled through DTC are considered to be “DTC eligible”. This electronic method of clearing securities speeds up the receipt of stock and cash, and thus accelerates the settlement process for investors and brokers, enabling the stock to be traded over a much wider selection of brokerage firms by coming into compliance with their requirements.

The Company’s common shares trade on the Canadian Securities Exchange under the symbol “VRDN” and on the OTCQB under the symbol VIRMF.

About Viridian Metals

Viridian Metals is a pioneer and leader in generative metal exploration with a focus on environmental responsibility and ethical practices. Founded with the intention of discovering new critical metals deposits with the potential to transform the metal supply chain. We leverage innovative technologies and methods to enhance efficiency and sustainability in jurisdictions eager to be leaders in supplying the energy transition. Viridian maintains expertise in a range of critical metals with a primary focus on copper, nickel and cobalt in the near term. Our commitment to integrity and transparency fosters strong partnerships with both local and global stakeholders.

For further information, please contact:

Viridian Metals
Tyrell Sutherland
CEO
Telephone: (613) 884-8332
Email: Info@viridianmetals.com

The CSE has not reviewed, approved or disapproved the contents of this news release

Cautionary Statement Regarding Forward-Looking Information

This news release contains statements which constitute “forward-looking information” within the meaning of applicable securities laws, including statements regarding the plans, intentions, beliefs and current expectations of Viridian with respect to future business activities and operating performance. 

Often, but not always, forward-looking information can be identified by the use of words such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, or “believes” or variations (including negative variations) of such words and phrases, or statements formed in the future tense or indicating that certain actions, events or results “may”, “could”, “would”, “might” or “will” (or other variations of the foregoing) be taken, occur, be achieved, or come to pass.

Forward-looking information in this news release includes, but is not limited to, statements regarding: (i) the continuation, scope and completion of the 2026 drill program at the Kraken Copper-Nickel Project; (ii) the timing of processing and delivery of samples to Actlabs, and the timing and content of assay results from holes not yet reported, including the step-out holes through VKS26-063; (iii) the expectation that visually identified sulphide mineralization will be confirmed by laboratory analysis; (iv) the potential further extension of hole VKS25-025 to test the main mineralized horizon; (v) the potential for a mineral resource estimate to be prepared at Kraken Main at some future date; (vi) the Company’s interpretations, including statements by management, regarding the geometry, continuity, thickness and depth extent of the mineralized horizon at Kraken Main, including true thicknesses of reported intervals, and the potential to expand mineralization through extension and step-out drilling; (vii) the metal prices, metallurgical recoveries and other assumptions underlying the copper-equivalent calculations disclosed herein, and the expectation that the metals included in those calculations have a reasonable potential to be recovered; (viii) the services to be provided by Oak Hill and the anticipated benefits of that engagement; (ix) the anticipated benefits of DTC eligibility, including improved liquidity of the Company’s shares in the United States; (x) the business plans and expectations of Viridian; and (xi) expectations for other economic, business and/or competitive factors in respect of Viridian.

In particular, readers are cautioned that there has been insufficient exploration at the Kraken Main Zone to define a mineral resource, and it is uncertain whether further exploration will result in any target being delineated as a mineral resource. There is no certainty that a mineral resource will be defined at Kraken Main. Visual estimates of sulphide mineralization are preliminary and are not a substitute for laboratory analysis. Copper-equivalent values are provided for illustrative purposes only and no metallurgical testwork has been completed at Kraken Main; actual recoveries may differ materially from the assumptions used.

Forward-looking information is based on currently available competitive, financial and economic data and operating plans, strategies or beliefs as of the date of this news release, but involve known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, performance or achievements of Viridian to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information. Such factors may be based on information currently available to Viridian, including information obtained from third-party industry analysts and other third-party sources, and are based on management’s current expectations or beliefs. Any and all forward-looking information contained in this news release is expressly qualified by this cautionary statement.

Investors are cautioned that forward-looking information is not based on historical facts but instead reflects management’s expectations, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Forward-looking information reflects Viridian’s current beliefs and is based on information currently available to it and on assumptions it believes to be not unreasonable in light of all of the circumstances. In some instances, material factors or assumptions are discussed in this news release in connection with statements containing forward-looking information. Such material factors and assumptions include, but are not limited to: the availability of drill rigs, qualified personnel and contractors on the timelines anticipated; the ability to obtain and maintain all required permits, surface access rights and Indigenous and community consents to conduct the planned program; weather, site access and logistical conditions in Labrador remaining consistent with the Company’s expectations; the accuracy of the Company’s geological models and the Company’s interpretations of prior drilling, geophysical surveys and modeled conductor plates; the continued availability of financing and working capital to fund the program through to completion; commodity prices for copper, nickel and cobalt remaining at levels supportive of the program; the absence of material adverse changes in applicable laws, regulations or political conditions; the ongoing conflicts in Ukraine and the Middle East and any actions taken by other countries in response thereto, such as sanctions or export controls; and anticipated and unanticipated costs and other factors referenced in the Company’s continuous disclosure record available on SEDAR+, including, but not limited to, those set forth in the Filing Statement under the caption “Risk Factors”. Although Viridian has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Forward-looking information contained herein is made as of the date of this news release and, other than as required by law, Viridian disclaims any obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise. There can be no assurance that forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward-looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. 

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/86497540-54d3-4b5d-84e5-0117f4bcc356

2 October 2026

Orange: information on the total number of shares and voting rights referred to in Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulations of the Autorité des Marchés Financiers.

In application of Article L. 22-10-46 of the French Commercial Code (Code de commerce), as from 3 April 2016, a double voting right is automatically granted to fully paid-up shares that have been held in registered form and under a single shareholder name for at least two years.

Date Number of shares Number of treasury shares without voting rights Theoretical number of voting rights [1] Number of voting rights exercisable
01/31/2026 2,660,056,599 1,457,248 3,180,394,670 3,178,937,422
02/28/2026 2,660,056,599 1,756,848 3,181,578,829 3,179,821,981
03/31/2026 2,660,056,599 1,756,848 3,179,834,278 3,178,077,430
04/30/2026 2,660,056,599 773,640 3,182,170,153 3,181,396,513
05/31/2026 2,660,056,599 590,180 3,182,009,609 3,181,419,429
06/30/2026 2,660,056,599 2,287,263 3,175,694,720 3,173,407,457
07/31/2026 2,660,056,599 2,282,263 3,175,201,190 3,172,918,927
08/31/2026 2,660,056,599 2,539,763 3,174,872,610 3,172,332,847
09/30/2026 2,660,056,599 7,217,263 3,174,460,855 3,167,243,592

[1] Calculated in accordance with the last paragraph of Article 223-11 of the General Regulations, on the basis of all the shares to which voting rights are attached, including shares without voting rights.

Attachment

 EXEL Industries
A French Société Anonyme with a share capital of €16,969,750
Registered office: 54, rue Marcel Paul – 51206 Epernay Cedex – France
Reims Companies Register (RCS): No. 095 550 356

 Number of shares and voting rights
 Article 223-16 of the AMF regulation

Date Total number of shares comprising the share capital Total number of voting rights
September 30, 2026 6,787,900 Theoretical voting rights: 9,897,118
Exercisable voting rights*: 9,889,783

* After deduction of shares without voting rights

Attachment

MCLEAN, Va., Oct. 02, 2026 (GLOBE NEWSWIRE) — HII (NYSE: HII) announced today that Greg Ennis has been promoted to senior vice president and chief financial officer of its Mission Technologies division. In this role, Ennis will lead the division’s financial organization and oversee accounting, financial reporting, financial planning and analysis, rates and budgets, and program cost control across the business.

“Greg’s leadership has been instrumental in strengthening our financial performance and driving disciplined growth,” said Andy Green, president of HII’s Mission Technologies division. “His strategic vision, deep understanding of our business, and strong command of government contracting uniquely position him to lead the division into its next chapter — advancing our growth strategy and delivering exceptional value for our customers, employees and shareholders.”

Ennis brings more than 25 years of experience in government contracting, accounting and financial management. He most recently served as vice president and controller for Mission Technologies, where he played a key role in strengthening the division’s financial operations and supporting its continued growth.

“Stepping into this role at such a pivotal moment for Mission Technologies is an honor,” Ennis said. “With a strong foundation and clear opportunities ahead, I look forward to partnering with our leadership team and employees to support our customers’ vital missions and advance the division’s long-term strategic priorities.”

Greg Ennis

A photo accompanying this release is available at: http://hii.com/news/hii-promotes-greg-ennis-to-chief-financial-officer-of-mission-technologies/.

About HII

HII is America’s largest shipbuilder, delivering the world’s most powerful ships and all-domain mission technologies, including unmanned systems, to U.S. and allied defense customers. HII is the largest producer of unmanned underwater vehicles for the U.S. Navy and the world.

With a more than 140-year history of advancing U.S. national security, HII builds and integrates defense capabilities extending from the core fleet to C6ISR, AI/ML, EW and synthetic training. Headquartered in Virginia, HII’s workforce is 45,000 strong. For more information, visit:

Contact:
Greg McCarthy
(202) 264-7126
gregory.j.mccarthy@hii-co.com 

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/3a7ba06c-eebe-4a70-a5ab-5a5b5bb4483c

BONDUELLE
Partnership limited by shares with a capital of 57 102 699,50 euros
Head office : La Woestyne – 59173 Renescure – France
447 250 044 RCS Dunkerque

2025-2026 Annual results
(July 1, 2025 – June 30, 2026)

The Bonduelle Group demonstrates its resilience, ending fiscal year 2025-2026 with stable sales and profitability

Message from Xavier Unkovic – Chief Executive Officer

Transforming ourselves to sustainably strengthen our performance

The past fiscal year unfolded in a particularly challenging environment, marked by the accumulation of major external shocks. In particular, our group faced the impact of unregulated imports of Chinese sweet corn, which put pressure on both volumes and selling prices, rising energy costs driven by international geopolitical tensions, and an exceptional heatwave that significantly affected agricultural yields for the 2026 harvest.

These adverse factors slowed the improvement of our profitability trajectory and temporarily weighed the delivery of our roadmap. However, they do not call into question the fundamentals of our strategy. On the contrary, they underscore the need to continue, with determination, the transformation already underway in order to strengthen the resilience of our business model in an environment that has remained particularly volatile over the past two years.

We are therefore continuing to execute our Transform to Win program to equip the company with the means to grow and enhance its competitiveness.
We have focused our resources on value-creating activities, brands and categories, evolved our portfolio through innovation to meet changing consumer expectations, and improved our operational efficiency.

This year’s financial performance does not yet fully reflect the potential of this transformation. However, the foundations are now firmly in place, our priorities are clear, and the first signs of progress are already visible.

In an environment that remains uncertain, we are fully committed to accelerating Bonduelle’s transformation. The group’s B Corp certification in January 2026 demonstrates our commitment to delivering profitable and sustainable growth, creating long-term value for all our stakeholders.

*****

On October 2, 2026, the Supervisory Board, under the chairmanship of Jean-Pierre Vannier, reviewed the statutory and consolidated financial statements for FY 2025-2026 as approved by the General Management and certified by the company’s statutory Auditors.

*****

Financial Performance

(in millions of euros) 2025-2026  
2024-2025
 
Variation
Sales 2,186.2 2,203.8 -0.8%
Current Operating Income 79.6 83.8 -5.0%
Net income from continuing operations 16.2 -11.5 +27.7
Current operating cash flow (1) 98.9 71.4 +27.5

The Bonduelle Group’s sales for fiscal year 2025-2026 (ended June 30, 2026) amounted to 2,186.2 million euros, a variation of +0.4% on a like-for-like basis (2). After accounting for currency exchange fluctuations, sales recorded a slight decrease of 0.8% on reported figures.

Net income rose by 27.7 million euros despite a 5.0% decrease in current operating income on reported figures, while the current operating margin reached 3.6% on reported figures.

Improved working capital requirements, resulting from a substantial reduction in inventory levels and rigorous investment control, contributed to the growth in current operating cash flow (1).

Business activity – Key figures

Activity by Geographical Region

Total consolidated sales
(in millions of euros)
2025-2026 2024-2025 Variation at current exchange rates Variation at constant exchange rates and scope
Europe Zone 1,372.1 1,354.5 1.3% 1.3%
Non-Europe Zone 814.0 849.3 -4.1% -1.0%
Total 2,186.2 2,203.8 -0.8% 0.4%

Activity by Operating Segment

Total consolidated sales
(in millions of euros)
2025-2026 2024-2025 Variation at current exchange rates Variation at constant exchange rates and scope
Canned 1,119.9 1,070.5 +4.6% +3.5%
Frozen 305.1 298.2 +2.3% +2.0%
Fresh processed 761.2 835.1 -8.8% -4.1%
Total 2,186.2 2,203.8 -0.8% +0.4%

Europe Zone

The Europe Zone, which accounted for 62.8% of the business activity over the period, rose by +1.3% on both reported figures and a like-for-like basis (2).

In a sluggish market, the canned foods segment delivered growth of 1.5%. This performance was driven by the growth of branded sales, including canned products, particularly under the Cassegrain brand, as well as the gradual normalization of private-label volumes following the introduction of tariffs on Chinese sweet corn imports. The large-scale activation plan rolled out for the Bonduelle brand across Europe, featuring a new visual identity, a powerful communication campaign, and innovations designed to meet evolving consumer expectations, is beginning to deliver tangible results in several markets.

The frozen products segment recorded growth of 2.1%, driven by the gradual ramp-up of Bonduelle branded innovations in the retail channel, in line with the strategic evolution of our portfolio, as well as by increased activity in the food service activity.

The fresh prepared salads business declined by 0.4%, impacted by competitive pressure and delisting losses. However, the Quarter 4 marked a gradual recovery in activity (+4.4%), supported by favorable weather conditions to the consumption of fresh prepared products and by the launch of new branded products in France and Italy.

Non-Europe Zone

The Non-Europe Zone, representing 37.2% of the business activity over FY 2025-2026, decline by 1.0% on like-to-like basis (2) (-4.1% on reported figures).

After a year of growth in 2024-2025, North American operations declined by 5.6% on a like-for-like basis (2) (-12.4% on reported figures) over the full fiscal year. Market conditions remained challenging, with inflation and the impact of several agricultural crises putting significant pressure on raw material availability, which weighed heavily on performance despite the strong momentum on our innovations and the recovery in the foodservice channel (+9.4%).

The Eurasia, Export and Mercosur region recorded growth of 8.7% on a like-for-like basis (2) (+13.6% on reported figures). This performance was driven by the growth of our brands and brand activation initiatives in a dynamic market environment, as well as by the success of several product innovations.

Current Operating Income

(in millions of euros) 2025-2026 2024-2025 Variation at current exchange rates Variation at constant exchange rates and scope
Sales 2,186.2 2,203.8 -0.8% +0.4%
Current operating income 79.6 83.8 -5.0% -10.5%
Current operating margin rate 3.6% 3.8% -16 bps -41 bps

For fiscal year 2025-2026, the Bonduelle Group reported a current operating income of 79.6 million euros at current exchange rates and 75.0 million euros at constant exchange rates, compared with 83.8 million euros in the previous fiscal year. Current operating margin stood at 3.6% on reported figures, representing a decline of 16 basis points at current exchange rates, and 3.4% on a like-for-like basis (2), representing a decline of 41 basis points compared with the previous fiscal year.

This decrease in current operating profitability reflects the following developments and contributions:

  • In Europe, despite sales growth driven in particular by higher value-added meal solutions, profitability declined compared with the previous fiscal year. This was mainly due to increased pricing pressure from private-label products, which drove prices downward, as well as elevated inventory levels in certain categories, particularly sweet corn;
  • Outside Europe, current operating profitability improved slightly. This performance was primarily driven by the strong results achieved in Eurasia, where prices increase implemented in an inflationary environment helped support margins while preserving market positions. By contrast, Bonduelle Americas’ profitability remained broadly stable, impacted by several agricultural crises and less favorable market conditions;
  • Operational performance improvement initiatives and overhead optimization programs continued to deliver benefits across the group. However, these gains were offset by the negative impact of underutilized industrial capacity, resulting from proactive inventory reduction measures.

Consolidated net income

As of June 30, 2026, in an uncertain economic environment that weighed on the pace of the group’s transformation plan, challenges in the North American fresh ready-to-eat business led to the recognition of a 35 million euros impairment charge on Bonduelle Americas’ goodwill. Combined with logistics optimization costs in the United States and restructuring and reorganization expenses, these items brought non-recurring charges for the period of -47.3 million euros. As a result, reported operating income amounted to 32.3 million euros compared with 73.0 million euros a year earlier.

Financial results improved to -29.2 million euros, compared with -35.1 million euros at the close of the previous fiscal year. Interest expense recorded during the year decreased significantly to -28.8 million euros, primarily driven by an improvement in the group’s financing cost (3.15% from 3.81%). Foreign exchange gains and losses were neutral during this period, compared with a 2.0 million euros loss in the prior year.

Income tax expense amounted to -24.4 million euros, compared with -20.1 million euros in the previous fiscal year.

Share of profit from equity-accounted investments contributed to 4.3 million euros, primarily reflecting Bonduelle’s share of earnings from its investment in Nortera Foods, which is accounted for using the equity method.

After taking into account net financial expense, income tax expense and the share of profit from equity-accounted investments, Bonduelle Group’s net income from continuing operations for fiscal year 2025-2026 amounted to a loss of 16.9 million euros, compared with a profit of 19.7 million euros in the previous fiscal year.

In accordance with IFRS 5, the contribution from businesses that have been sold, are held for sale or have been discontinued is reported under “Net income from discontinued operations”. Accordingly, items recorded under this heading for the fiscal year amounted to 33.1 million euros. These mainly include the capital gain arising from the disposal of the packaged salad business in France, as well as the annual result of BF Agricola in Spain, whose operations were discontinued during the year.

Including net income from discontinued operations, Bonduelle Group’s consolidated net income for fiscal year 2025-2026 amounted to 16.2 million euros, compared with the loss of 11.5 million euros in the previous fiscal year and the loss of 111 million euros two years earlier.

Financial situation

  June 30, 2024
reported
June 30, 2025
reported
June 30, 2026
reported
Net debt (in millions of euros) 561.9 571.2 577.4
Gearing (3) 0.88 0.94 0.92
Leverage ratio (4) 3.57 3.38 3.58

Net debt, after taking into account IFRS 5 standards, amounted to 577.4 million euros (compared with 571.2 million euros the previous fiscal year) and the leverage ratio (4) stood at 3.58 compared to 3.38 for the previous fiscal year.  

Other significant information

Sale of the packaged salad business in France

In accordance with its “Transform to win” transformation plan, the group completed the sale of its packaged salad business in France to the LSDH group on July 17, 2025, after several years of declining results in this segment.

Annual General Meeting on December 3, 2026 – Dividend

During the Annual General Meeting, to be held on December 3, 2026, a dividend of 0.25 euro per share will be proposed.

Outlook

In a context that continues to be marked by significant agricultural and geopolitical uncertainties, the Bonduelle Group will focus its efforts on maintaining profitability and strengthening its financial fundamentals, particularly through improved cash flow generation and further debt reduction.

(1) current operating income plus depreciation and the change in working capital requirements, and after deduction of investments
(2) at constant currency exchange rate and scope of consolidation basis. Net sales in foreign currency over the given period are translated into the rate of exchange for the comparable period. The impact of business acquisitions (or gain of control) and divestments is restated as follows:

  • For businesses acquired (or gain of control) during the current period, net sales generated since the acquisition date are excluded from the organic growth calculation;
  • For businesses acquired (or gain of control) during the prior fiscal year, net sales generated during the current period up until the first anniversary date of the acquisition are excluded;
  • For businesses divested (or loss of control) during the prior fiscal year, net sales generated in the comparative period of the prior fiscal year until the divestment date are excluded;
  • For businesses divested (or loss of control) during the current fiscal year, net sales generated in the period commencing 12 months before the divestment date up to the end of the comparative period of the prior fiscal year are excluded.

(3) net financial debt / equity
(4) net financial debt / recurring EBITDA

Alternative performance indicators: the group presents in its financial notices performance indicators not defined by accounting standards. The main performance indicators are detailed in the financial reports available on www.bonduelle.com

 

Next financial events:
                                                                                                                                                                                                                                                      
– Information meeting:                                                                                 October 5, 2026

– 2026-2027 1st Quarter sales:                                                                    November 5, 2026 (after market closing)
– Annual General Meeting:                                                                           December 3, 2026
– 2026-2027 1st Half Year Sales and Results:                                             February 25, 2027 (after market closing)

Find all annual results
And the schedule of financial publications on www.bonduelle.com

About the Bonduelle Group

The Bonduelle Group is, above all, a family story from the north of France that has lasted for 7 generations. Present in nearly 100 countries, we are proud of our iconic brands: Bonduelle, Cassegrain, and Globus. We collaborate with more than 2,000 passionate growers to offer you vegetables and pulses harvested at the peak of their flavor and nutrition.

Because we believe that every meal is an opportunity to make a difference, we are committed to inspire the transition toward a plant-rich diet, for the well-being of all and planet health. 100% B Corp certified since January 1, 2026, we are affirming our commitment to a more sustainable and responsible model.

For the 2025-2026 fiscal year, the company generated sales of 2.2 billion euros.  

Bonduelle is listed on Euronext Paris compartment B
Euronext indices: CAC MID & SMALL – CAC FOOD PRODUCERS – CAC ALL SHARES
Bonduelle is part of the Gaïa non-financial performance index and employees shareholder index (IAS)
Code ISIN: FR0000063935 – Code Reuters : BOND.PA – Code Bloomberg : BON FP

Attachment

Sheen Dental and Hansen Incarnati join SDL as the Company plans to bring outsourced production to Sarasota

TAMPA, Fla., Oct. 02, 2026 (GLOBE NEWSWIRE) — Standard Dental Labs Inc. (OTCQB: TUTH) (“SDL” or the “Company”) today announced the acquisition, effective October 2, 2026, of substantially all of the operating assets of Dr. Tooth, LLC, the dental laboratory business also known as Sheen Dental Laboratory and Hansen Incarnati. The acquisition expands SDL’s customer base and advances its strategy of consolidating Florida dental laboratories around regional production facilities.

Based on current operating levels, management estimates that the acquired business adds just over $800,000 in annualized revenue. Combined with SDL’s previously announced annualized revenue estimate of approximately $822,000 for its existing operations, the acquisition brings the Company’s estimated annualized revenue base to more than $1.6 million, nearly double the prior estimate. These figures reflect management’s estimates of operating activity extended over 12 months and are not a forecast of revenue to be reported for calendar 2026.

SDL plans to move production for the acquired business to its Sarasota facility, bringing work currently outsourced to China into the Company’s Florida operations. Management believes domestic production can strengthen quality control and communication with dentists, help recover former customer relationships and increase utilization of the Sarasota facility. By adding volume to its existing production infrastructure, SDL expects the acquisition to improve the facility’s profitability as integration progresses.

Management, which will included the existing Dr. Tooth management team of Denis Thaxton and Gavin White, believes these changes create an opportunity to rebuild the acquired business to more than $1.1 million in annualized revenue. Achieving that objective will depend on retaining current accounts, recovering customers and successfully transitioning production.

“Our focus is to bring this work back to Florida and give dentists direct access to the people making their restorations,” said James D. Brooks, President and Chief Executive Officer of Standard Dental Labs Inc. “We are adding an established customer base to our Sarasota operation, where the additional production can improve the economics of the facility. We also see a clear opportunity to win back business by giving customers the domestic production and responsive service they want.”

The transaction was structured as an asset purchase with a combination of cash and SDL common stock, including performance conditions tied to retained customer revenue.

About Standard Dental Labs Inc

Standard Dental Labs Inc. is a Florida-focused dental laboratory company pursuing growth through acquisitions and investment in domestic production capabilities. SDL serves dental practices through its laboratory operations and is focused on digital workflows, quality and responsive service. Its common stock trades on the OTCQB under the symbol TUTH.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws, including statements regarding anticipated revenue growth, future acquisitions, integration efforts, scalability, financing initiatives, operational synergies, and long-term shareholder value. Forward-looking statements generally can be identified by words such as “expects,” “intends,” “plans,” “believes,” “anticipates,” “will,” “may,” “continue,” and similar expressions.

These statements are based on current expectations, estimates, and assumptions that are subject to significant risks and uncertainties, many of which are beyond the Company’s control. Actual results may differ materially from those expressed or implied by such forward-looking statements due to a variety of factors, including integration risks, customer retention, operational performance, financing availability, regulatory considerations, market conditions, and other risks disclosed in the Company’s filings with the Securities and Exchange Commission and disclosures published through OTC Markets.

The Company’s Regulation A offering statement referenced herein does not constitute an offer to sell or the solicitation of an offer to buy securities except pursuant to the qualified offering circular. Any investment should be made only after careful review of the offering materials and risk factors contained therein.

Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date made. Standard Dental Labs Inc. undertakes no obligation to update or revise forward-looking statements except as required by law.

Investor and Media Contact

Standard Dental Labs Inc.
424 E Central Blvd, Suite 308, Orlando, FL 32801
Phone: (407) 789-1923
Email: info@sdl.care
Investors: https://sdl.care/investors

SOURCE: Standard Dental Labs Inc.

SEATTLE, Oct. 02, 2026 (GLOBE NEWSWIRE) — Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that data from the Company’s lapemelanotide zapixetar (also known as [²¹²Pb]VMT01) program have been accepted for presentation at the Society for Immunotherapy of Cancer (SITC) 41st Annual Meeting & Pre-Conference Programs taking place November 4 to 8, 2026, in Phoenix, Arizona. SITC plans to release further details for regular abstracts on November 3, 2026.

Presenting Author Abstract Title Presentation Details
Matthew Block, Department of Oncology, Mayo Clinic A phase I/IIa trial of [212Pb]VMT01 MC1R-targeted alpha-particle mono- and combination-therapy with nivolumab in participants with previously treated unresectable or metastatic melanoma Abstract Number: 571
Presentation type: Poster presentation
Date: Friday, Nov. 6, 2026
Location: PCC-North Building-Lower Level-Exhibition Halls
4-5-6


About [²¹²Pb]VMT-01

Perspective designed [212Pb]VMT01 to target and deliver 212Pb to metastatic melanoma tumor sites expressing MC1R, a protein that can be overexpressed in metastatic melanoma tumors.1 The Company is conducting a multi-center, open-label dose escalation, dose expansion study (clinicaltrials.gov identifier NCT05655312) in patients with histologically confirmed melanoma and MC1R-positive imaging scans.

Interim analysis with a data cut-off date of March 25, 2026 was presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in May 2026. Highlights from the ASCO analysis included the following:

  • Patients were heavily pre-treated prior to entering trial with a median of 4 prior lines of systemic therapy (including prior checkpoint inhibitors)
  • One new response was observed early in the 3.0 mCi monotherapy cohort, in addition to a previously reported response, for a total of two responders out of seven treated patients
  • Six patients (86%) experienced stable disease or partial response out of the seven patients in the 3.0 mCi monotherapy cohort; four patients completed all three treatments with 24 weeks or more of follow-up since their first treatment, and two remained on treatment and in study
  • [²¹²Pb]VMT01 was well-tolerated with no dose limiting toxicities (DLTs), no discontinuations due to adverse events, and no Grade 4 or Grade 5 treatment emergent adverse events (TEAEs)
  • Eight (30%) patients out of a total of 27 patients treated experienced Grade 3 TEAEs

About Perspective Therapeutics, Inc.

Perspective Therapeutics, Inc. is a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body. The Company has proprietary technology that utilizes the alpha-generating isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting moieties. The Company is also developing complementary imaging techniques that incorporate the same targeting moieties, which provides the opportunity to personalize treatment and optimize patient outcomes. This “theranostic” approach enables visualization of the specific tumor and subsequent treatment, potentially improving efficacy and minimizing toxicity.

The Company is advancing a portfolio of clinical-stage programs in the U.S., including bamzireotide navoxetan (VMT-α-NET, neuroendocrine tumors), lapemelanotide zapixetar (VMT01, melanoma), and PSV359 (solid tumors).

The Company is expanding its regional finished drug product candidate supply network, enabled by its proprietary 224Ra/212Pb generator platform used to manufacture clinical drug product candidates, to support the delivery of patient-ready drug product candidates for clinical trials and, if approved, commercial operations.

For more information, please visit the Company’s website at www.perspectivetherapeutics.com.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Words such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential,” or “continue” or the negative of these terms or other similar expressions are intended to identify forward-looking statements, though not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include statements concerning, among other things, the Company’s clinical development plans and the expected timing for the release of additional data from its clinical programs; the Company’s regional distribution and manufacturing capabilities; and other statements that are not historical fact.

The Company may not actually achieve the plans, intentions, or expectations disclosed in the forward-looking statements, and you should not place undue reliance on the forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the Company’s actual results to differ materially from the results described in or implied by the forward-looking statements. Known risk factors include that the Company’s preclinical development plans and clinical trials may be more costly or take longer to complete than anticipated, or may never be completed, or may not generate results that warrant future development of the tested product candidate; the Company may elect to change its strategy regarding its product candidates and development activities; economic and market conditions may worsen; regulatory agencies may issue decisions that negatively impact the Company’s product candidates and clinical development plans; and risks related to the sufficiency of the Company’s cash resources for its future operating expenses and capital expenditures. A more complete discussion of the risks and uncertainties facing the Company appears under the heading “Risk Factors” in the Company’s most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the “SEC”), in the Company’s other filings with the SEC, and in the Company’s future reports to be filed with the SEC and available at www.sec.gov. Forward-looking statements contained in this news release are made as of this date. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Media and Investor Relations Contacts:

Perspective Therapeutics IR:
Annie J. Cheng, CFA
ir@perspectivetherapeutics.com

ENTENTE Network of Companies
Katie Morris, PhD
katiemorris@ententeinc.com


1 Su DG, Djureinovic D, Schoenfeld D, et al. Melanocortin-1 Receptor Expression as a Marker of Progression in Melanoma. JCO Precis Oncol. 2024;8:e2300702. doi:10.1200/PO.23.00702.

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.